

Cynthia S. Betz
Mark M. Makhail
McCARTER & ENGLISH, LLP
4 Gateway Center
100 Mulberry Street
Newark, NJ 07102
Tel: 973-622-4444
cbetz@mccarter.com
mmakhail@mccarter.com
Attorneys for Plaintiffs

Eric I. Abraham
Stephanie-Rose C. Orlando
William P. Murtha
HILL WALLACK LLP
21 Roszel Road
Princeton, NJ 08540
Telephone: (609) 924-0808
eabraham@hillwallack.com
sorlando@hillwallack.com
wmurtha@hillwallack.com
Attorneys for Defendants

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

GENENTECH, INC., HOFFMANN-LA
ROCHE INC., and BIOGEN INC.

Plaintiffs

v.

DR. REDDY'S LABORATORIES, INC.,
DR. REDDY'S LABORATORIES SA, DR.
REDDY'S LABORATORIES LTD.,
FRESENIUS KABI USA, LLC,
FRESENIUS KABI SWISSBIOSIM
GmbH, and FRESENIUS KABI
DEUTSCHLAND GmbH,

Defendants.

Civil Action No. 1:23-cv-22485-
RMB-MJS

Judge Renée Marie Bumb

STIPULATION OF DISMISSAL

STIPULATION OF DISMISSAL

This stipulation is made by and between Plaintiffs Genentech, Inc., Hoffmann-La Roche Inc. ("HLR"), and Biogen Inc. ("Biogen"), (collectively, "Plaintiffs") and Defendants Dr. Reddy's Laboratories, Inc. ("DRL Inc."), Dr. Reddy's Laboratories SA ("DRL SA"), Dr. Reddy's Laboratories Ltd. ("DRL Ltd."), Fresenius Kabi USA, LLC ("Fresenius USA"), Fresenius Kabi SwissBioSim GmbH ("Fresenius Switzerland"), and Fresenius Kabi Deutschland GmbH ("Fresenius Germany"), (collectively, "Defendants" and together with "Plaintiffs", the "Parties").

WHEREAS, DRL SA submitted Biologics License Application (the “DRL Rituximab BLA”), seeking approval from the U.S. Food and Drug Administration (“FDA”) for a proposed biosimilar rituximab product (the “Biosimilar Product”);

WHEREAS, DRL SA listed Rituxan® as the reference product in the BLA;

WHEREAS, counsel for DRL SA served a Notice of Commercial Marketing pursuant to 42 U.S.C. § 262(l)(8)(A);

WHEREAS, in light of DRL SA’s submission of the BLA and notice pursuant to 42 U.S.C. § 262(l)(8)(A), Plaintiffs asserted in this Action claims for patent infringement and declaratory judgment against Defendants;

WHEREAS, the Parties enter into this joint stipulation of dismissal subject to a settlement agreement (“Agreement”);

WHEREAS, in consideration of the terms and conditions set forth in the Agreement, Plaintiffs have agreed to dismiss all claims asserted in this action.

SO STIPULATED.

Dated:

Respectfully submitted,

/s/ Cynthia S. Betz

/s/ Eric I. Abraham

Plaintiffs Genentech, Inc., et al.	Defendants Dr. Reddy’s Lab. Inc., et al.
Cynthia S. Betz Mark M. Makhail McCARTER & ENGLISH, LLP 4 Gateway Center 100 Mulberry Street Newark, NJ 07102 Tel: 973-622-4444 cbetz@mccarter.com mmakhail@mccarter.com	Eric I. Abraham Stephanie-Rose C. Orlando William P. Murtha HILL WALLACK LLP 21 Roszel Road Princeton, NJ 08540 Telephone: (609) 924-0808 eabraham@hillwallack.com sorlando@hillwallack.com wmurtha@hillwallack.com

David I. Gindler (*pro hac vice*)
Lauren Drake (*pro hac vice*)
John Lu (*pro hac vice*)
**ORRICK, HERRINGTON &
SUTCLIFFE LLP**
355 South Grand Avenue, Suite 2700
Los Angeles, California 90071-1596
dgindler@orrick.com
jlu@orrick.com

Pengweixi Sun (*pro hac vice*)
Jonathan Liu (*pro hac vice*)
**ORRICK, HERRINGTON &
SUTCLIFFE LLP**
1000 Marsh Road
Menlo Park, CA 94025
(650) 614-7400

Jessica Stern (*pro hac vice*)
**ORRICK, HERRINGTON &
SUTCLIFFE LLP**
The Orrick Building
405 Howard Street
San Francisco, CA 94105
(415) 773-5700

*Attorneys for Plaintiffs Genentech, Inc.,
Hoffmann-La Roche, Inc., and Biogen Inc.*

William A. Rakoczy (*pro hac vice*)
Jake R. Ritthamel (*pro hac vice*)
**RAKOCY MOLINO MAZZOCHI SIWIK
LLP**
6 W. Hubbard Street, Suite 500
Chicago, IL 60654
wrakoczy@rmmslegal.com
(312) 527-2157

*Attorneys for Defendants Dr. Reddy's
Laboratories, Inc., Dr. Reddy's Laboratories
SA, Dr. Reddy's Laboratories Ltd., Fresenius
Kabi USA, LLC, Fresenius Kabi SwissBioSim
GmbH, and Fresenius Kabi Deutschland GmbH*